Company / Capital Expenditures
Fulcrum Therapeutics, Inc. Capital Expenditures History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$314.0K
FY2025
5-year range
$278.0K / $2.0M
FY2021-FY2025
Trend
+12.9%
vs FY2024
Sector context
#149 of 194
Health Care
What the data says
Fulcrum Therapeutics, Inc.'s capital expenditures of $314,000 is lower than 77% of companies in the Health Care sector (FY2025). Capital Expenditures returned to growth in FY2025 after 2 years of decline, reaching $314,000.
Based on SEC 10-K filings.
$314,000 in FY2025 with a 5-year CAGR of -25.2%.
Declined from $508,000 to $314,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -45.7%
- 5-Year CAGR
- -25.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 194This company $314.0K Sector average $117.5M
▼
-99.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -25.2%, indicating a declining trend.
- In FY2025, capital expenditures increased 12.9% year-over-year.
- Ranks #149 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $314.0K | +12.9% |
| FY2024 | $278.0K | -45.3% |
| FY2023 | $508.0K | -74.1% |
| FY2022 | $2.0M | +14.6% |
| FY2021 | $1.7M | +27.6% |
| FY2020 | $1.3M | +57.3% |
| FY2019 | $853.0K | -90.5% |
| FY2018 | $9.0M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026